For instance, alterations in PTEN are more common in triple‐negative breast cancer (TNBC) varying between 35% and 67% compared with ER‐positive (ER+) breast tumors (29‐44%) and HER2‐positive (HER2+) breast carcinomas (19–22%) 4. This evidence concerns the gene ERBB2 and breast neoplasm.